AveXis axed top R&D execs before Zolgensma was approved

Wednesday, 14. August 2019 19:14

Swiss pharmaceutical company Novartis International AG's subsidiary AveXis Inc. announced on Wednesday that it has removed two of its senior research and development executives amid reports indicating that the drugmaker knew its application for its gene therapy contained data manipulation.

The company said that Page Bouchard has been appointed as the company's Senior Vice President of research and Chief Scientific Officer instead of Brian Kaspar and Allan Kaspar, two executives ousted after the scandal. According to the statement, Kaspar brothers have not been involved in any operations at AveXis since early May 2019.

Earlier, the United States Food and Drug Administration (FDA) revealed that errors in the application for the world's most expensive drug Zolgensma may have impacted the accuracy of certain data reviewed by the FDA. Novartis notified federal regulators of these issues more than a month after Zolgensma was approved.

Related Links: Novartis AG
Breaking the News / MA